# Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients

> **NCT03630159** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 12 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Tisagenlecleucel
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03630159
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-09
- **Primary completion:** 2021-07-20
- **Final completion:** 2021-07-20
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03630159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03630159, "Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03630159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*